Virax Biolabs Group Limited Ordinary Shares
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, ot… Read more
Virax Biolabs Group Limited Ordinary Shares (VRAX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.576x
Based on the latest financial reports, Virax Biolabs Group Limited Ordinary Shares (VRAX) has a cash flow conversion efficiency ratio of -0.576x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.92 Million) by net assets ($5.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Virax Biolabs Group Limited Ordinary Shares - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Virax Biolabs Group Limited Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Virax Biolabs Group Limited Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Virax Biolabs Group Limited Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Spectra7 Microsystems Inc
OTCQB:SPVNF
|
-0.792x |
|
Panther Metals Ltd
AU:PNT
|
-0.032x |
|
NATL BK CANADA (NBC.SG)
STU:NBC
|
0.270x |
|
ARROW ELECTRONICS
MU:ARW
|
0.013x |
|
Stamper Oil & Gas Corp
PINK:STMGF
|
-0.082x |
|
Syra Health Corp. Class A Common Stock
NASDAQ:SYRA
|
-0.046x |
|
ARROW ELECTRONICS - Dusseldorf Stock Exchang
DU:ARW
|
0.013x |
|
AMPHENOL-A - Dusseldorf Stock Exchang
DU:XPH
|
0.074x |
Annual Cash Flow Conversion Efficiency for Virax Biolabs Group Limited Ordinary Shares (2020–2025)
The table below shows the annual cash flow conversion efficiency of Virax Biolabs Group Limited Ordinary Shares from 2020 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $5.46 Million | $-4.56 Million | -0.835x | +31.27% |
| 2024-03-31 | $5.14 Million | $-6.25 Million | -1.216x | -158.97% |
| 2023-03-31 | $8.90 Million | $-4.18 Million | -0.469x | -169.43% |
| 2022-03-31 | $-1.20 Million | $-809.07K | 0.676x | -10.96% |
| 2021-03-31 | $-777.32K | $-590.19K | 0.759x | +23.90% |
| 2020-03-31 | $-1.22 Million | $-744.61K | 0.613x | -- |